OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics
Joint Authors
Sprangers, Ben
Herman, Jean
Waer, Mark
Louat, Thierry
Van Belle, Kristien
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-12
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
B cells are pathogenic in various disease processes and therefore represent an interesting target for the development of novel immunosuppressants.
In the search for new therapeutic molecules, we utilized an in vitro B cell activation assay with ODN2006-stimulated Namalwa cells to screen a chemical library of small molecules for B cell modulating effects.
OSU-T315, described as an inhibitor of integrin-linked kinase (ILK), was hereby identified as a hit.
On human and murine primary B cells, OSU-T315 potently suppressed the proliferation and the production of antibodies and cytokines upon stimulation, suggesting that ILK could be a promising target in the modulation of B cell activity.
Mice with B cell-specific knockout of ILK were generated.
Surprisingly, knockout of ILK in murine B cells did not affect B cell function as assessed by several in vivo and ex vivo B cell assays and did not alter the B cell immunosuppressive activity of OSU-T315.
In conclusion, OSU-T315 displays potency as B cell modulator, probably through a mechanism of action independent of ILK, and might serve as lead drug molecule for the development of novel B cell-selective drugs.
American Psychological Association (APA)
Van Belle, Kristien& Herman, Jean& Waer, Mark& Sprangers, Ben& Louat, Thierry. 2018. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1191840
Modern Language Association (MLA)
Van Belle, Kristien…[et al.]. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics. Journal of Immunology Research No. 2018 (2018), pp.1-14.
https://search.emarefa.net/detail/BIM-1191840
American Medical Association (AMA)
Van Belle, Kristien& Herman, Jean& Waer, Mark& Sprangers, Ben& Louat, Thierry. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1191840
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191840